Thyroid Eye Disease (TED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Thyroid Eye
Disease (TED) Market Outlook
Thelansis’s “Thyroid Eye Disease
(TED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2026 To 2036” covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Thyroid Eye
Disease (TED) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Thyroid Eye
Disease (TED) Overview
Thyroid eye disease (TED) is an
autoimmune orbital disorder primarily linked to Graves’ hyperthyroidism, driven
by autoantibodies that simultaneously target TSH and IGF-1 receptors on orbital
fibroblasts. This triggers profound glycosaminoglycan accumulation,
adipogenesis, and tissue inflammation, causing extraocular muscle enlargement,
proptosis, and elevated intraorbital pressure. While classic models describe a
biphasic course—moving from an active inflammatory phase to an inactive
fibrotic plateau—the therapeutic boundary between these stages has faded.
Diagnosis combines clinical activity scores (CAS) with orbital MRI or CT
imaging demonstrating muscle enlargement with characteristic tendon sparing. While
intravenous methylprednisolone pulses address acute inflammation, targeted
IGF-1R monoclonal antibodies have revolutionized management. Beyond
Amgen’s pioneer drug Tepezza (teprotumumab)—which recently advanced
into a convenient subcutaneous on-body injector formulation—the regulatory
landscape expanded with the FDA approval of Lumvoa (veligrotug-vvze). Lumvoa is
a landmark advance, clearing a shorter 12-week dosing course and demonstrating
definitive efficacy in reducing proptosis and fully resolving diplopia across
both active and chronic, inactive disease stages. While
sequential corrective surgeries remain vital for fixed structural sequelae,
modern multi-stage biologic intervention yields an exceptionally favorable
prognosis.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment